

Title (en)  
HETEROCYCLIC COMPOUND

Title (de)  
HETEROCYCLISCHE VERBINDUNG

Title (fr)  
COMPOSÉ HÉTÉROCYCLIQUE

Publication  
**EP 2202223 A4 20110810 (EN)**

Application  
**EP 08838911 A 20081017**

Priority  
• JP 2008068901 W 20081017  
• US 96089707 P 20071018

Abstract (en)  
[origin: EP2202223A1] The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.

IPC 8 full level  
**C07D 205/04** (2006.01)

CPC (source: EP US)  
**A61P 3/04** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 27/12** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 205/04** (2013.01 - EP US); **C07D 207/08** (2013.01 - EP US); **C07D 207/12** (2013.01 - EP US); **C07D 211/22** (2013.01 - EP US); **C07D 211/44** (2013.01 - EP US); **C07D 211/46** (2013.01 - EP US); **C07D 211/78** (2013.01 - EP US); **C07D 211/88** (2013.01 - EP US); **C07D 401/06** (2013.01 - EP US); **C07D 401/12** (2013.01 - EP US); **C07D 403/06** (2013.01 - EP US); **C07D 403/12** (2013.01 - EP US); **C07D 413/04** (2013.01 - EP US); **C07D 413/06** (2013.01 - EP US); **C07D 413/10** (2013.01 - EP US); **C07D 413/12** (2013.01 - EP US); **C07D 417/04** (2013.01 - EP US); **C07D 417/06** (2013.01 - EP US); **C07D 417/08** (2013.01 - EP US); **C07D 417/10** (2013.01 - EP US); **C07D 471/04** (2013.01 - EP US); **C07D 495/04** (2013.01 - EP US); **C07D 513/04** (2013.01 - EP US)

Citation (search report)  
• [I] WO 2007106705 A1 20070920 - BOEHRINGER INGELHEIM INT [DE], et al  
• [ID] WO 02055501 A2 20020718 - AMGEN INC [US]  
• [I] WO 02066470 A1 20020829 - AMGEN INC  
• [I] WO 02068406 A2 20020906 - AMGEN INC [US]  
• [I] WO 2004007458 A1 20040122 - AMGEN INC [US]  
• [I] WO 2004007481 A2 20040122 - AMGEN INC [US]  
• [E] WO 2009042444 A2 20090402 - SIRION THERAPEUTICS INC [US], et al  
• [E] WO 2009117676 A2 20090924 - FOREST LAB HOLDINGS LTD, et al  
• See references of WO 2009051244A1

Cited by  
EP3638238A4; EP2291200A4; EP3638239A4; US8338622B2; US11389444B2; US11951100B2; US8541388B2; US12016853B2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**EP 2202223 A1 20100630; EP 2202223 A4 20110810; EP 2202223 B1 20170125**; JP 5374377 B2 20131225; JP WO2009051244 A1 20110303; US 2010292206 A1 20101118; US 2014066420 A1 20140306; US 8586571 B2 20131119; US 9487509 B2 20161108; WO 2009051244 A1 20090423

DOCDB simple family (application)  
**EP 08838911 A 20081017**; JP 2008068901 W 20081017; JP 2009538178 A 20081017; US 201314055585 A 20131016; US 73848608 A 20081017